Microtiter plates (Immulon; Thermo Electron Corp., Milford, MA) were coated with 100 μL of 1 μg/mL rhCTGF or its fragments (N, N-terminal half fragment, rhN-CTGF; C, C-terminal half fragment), rhTGFβ2, or rhTGFβRII in 50 mM NaHCO3 buffer (pH 9.6) at 4°C overnight, and blocked with 200 μL binding buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 2% BSA, 0.05% Tween 20) for 1 hour at 37°C. Biotinylated rhTGFβ2, rhTGFβRII (R&D Systems), or rhCTGF were added to the wells in a total volume of 100 μL binding buffer and incubated for 3 hours at 37°C. To confirm specificity, an equal amount of TGFβRII (1 μg/mL) was denatured at 95°C for 5 minutes before biotinylation. In addition, basic fibroblast growth factor (bFGF; R&D Systems) was biotinylated and used as a control. The wells were washed with binding buffer and then incubated with 100 μL of alkaline phosphatase (AP)–conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA). Bound AP was monitored using p-nitrophenyl phosphate AP substrate (Chemicon). Biotinylation of rhTGFβ2, rhTGFβRII, and rhCTGF was performed with sulfo-NHS-LC-biotin (Pierce, Rockford, IL), according to the manufacturer's protocol.